These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 2829381

  • 1. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D.
    Thromb Haemost; 1987 Oct 28; 58(3):947-50. PubMed ID: 2829381
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D, Stassen JM, De Cock F.
    Thromb Haemost; 1987 Oct 28; 58(3):943-6. PubMed ID: 3124288
    [Abstract] [Full Text] [Related]

  • 3. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
    Juhan-Vague I, Stassen JM, Alessi MC, de Cock F, Serradimigni A, Collen D.
    J Mal Vasc; 1987 Oct 28; 12 Suppl B():64-5. PubMed ID: 2834493
    [Abstract] [Full Text] [Related]

  • 4. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I, Stassen JM, Alessi MC, Elias A, Aillaud MF, Serradimigni A, Collen D.
    Semin Thromb Hemost; 1989 Oct 28; 15(4):390-4. PubMed ID: 2554499
    [No Abstract] [Full Text] [Related]

  • 5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 6. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 8. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 9. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET, Mack DL, Sobel BE.
    Thromb Haemost; 1989 Nov 24; 62(3):909-16. PubMed ID: 2512679
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D.
    Prog Hemost Thromb; 1986 Nov 24; 8():1-18. PubMed ID: 3104986
    [No Abstract] [Full Text] [Related]

  • 14. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V, Pannell R.
    Thromb Haemost; 1987 Jun 03; 57(3):372-3. PubMed ID: 3116707
    [No Abstract] [Full Text] [Related]

  • 15. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
    Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, Rössler W, Wolf H, Welzel D, Just H, Gurewich V.
    Klin Wochenschr; 1988 Jun 03; 66 Suppl 12():109-14. PubMed ID: 3126340
    [Abstract] [Full Text] [Related]

  • 16. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
    Agnelli G, Pascucci C, Colucci M, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1992 Sep 07; 68(3):331-5. PubMed ID: 1440500
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    Thromb Haemost; 1988 Oct 31; 60(2):247-50. PubMed ID: 3146141
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
    Vanderschueren S, Collen D.
    Thromb Haemost; 1996 May 31; 75(5):816-9. PubMed ID: 8725729
    [Abstract] [Full Text] [Related]

  • 20. [Experimental study on liquefaction of intracranial hematoma: usefulness of tissue-plasminogen activator (t-PA), a hematolytic agent, and its combination].
    Ebina K, Okabe S, Manabe H, Iwabuchi T.
    No Shinkei Geka; 1990 Oct 31; 18(10):927-34. PubMed ID: 2122269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.